Market revenue in 2023 | USD 75.3 million |
Market revenue in 2030 | USD 215.7 million |
Growth rate | 16.2% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.89% in 2023. Horizon Databook has segmented the India hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
India has a flourishing pharmaceutical sector owing to the emergence of generic manufacturers and the presence of leading pharmaceutical players. The growth of India hereditary angioedema therapeutics market is driven by increasing prevalence of hereditary diseases in the country, coupled with several awareness campaigns arranged by governments to promote awareness regarding the condition.
Healthcare reforms in India are underway, as healthcare expenditure is expected to grow at a rate of over 15% yearly. In addition, high use of generic substitutes and easy availability of drugs in India are some of the factors anticipated to impact market growth positively.
Horizon Databook provides a detailed overview of country-level data and insights on the India hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into India hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account